KR102407053B1 - 갑상선 베타-작용제의 사용 - Google Patents

갑상선 베타-작용제의 사용 Download PDF

Info

Publication number
KR102407053B1
KR102407053B1 KR1020187033321A KR20187033321A KR102407053B1 KR 102407053 B1 KR102407053 B1 KR 102407053B1 KR 1020187033321 A KR1020187033321 A KR 1020187033321A KR 20187033321 A KR20187033321 A KR 20187033321A KR 102407053 B1 KR102407053 B1 KR 102407053B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
compound
optionally substituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033321A
Other languages
English (en)
Korean (ko)
Other versions
KR20190017748A (ko
Inventor
브라이언 리안
로셸 핸리
미샤 디너만
Original Assignee
바이킹 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이킹 테라퓨틱스 인코포레이티드 filed Critical 바이킹 테라퓨틱스 인코포레이티드
Publication of KR20190017748A publication Critical patent/KR20190017748A/ko
Application granted granted Critical
Publication of KR102407053B1 publication Critical patent/KR102407053B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
KR1020187033321A 2016-04-22 2017-04-24 갑상선 베타-작용제의 사용 Active KR102407053B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326431P 2016-04-22 2016-04-22
US62/326,431 2016-04-22
PCT/US2017/029102 WO2017185083A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (2)

Publication Number Publication Date
KR20190017748A KR20190017748A (ko) 2019-02-20
KR102407053B1 true KR102407053B1 (ko) 2022-06-10

Family

ID=60117062

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033321A Active KR102407053B1 (ko) 2016-04-22 2017-04-24 갑상선 베타-작용제의 사용

Country Status (10)

Country Link
US (1) US20190134069A1 (https=)
EP (1) EP3445372B1 (https=)
JP (1) JP2019515915A (https=)
KR (1) KR102407053B1 (https=)
CN (3) CN110200978B (https=)
AU (2) AU2017252122B2 (https=)
BR (1) BR112018071559B1 (https=)
CA (1) CA3021677C (https=)
MX (1) MX2018012904A (https=)
WO (1) WO2017185083A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445373B1 (en) 2016-04-22 2024-08-21 Viking Therapeutics, Inc. Use of thyroid beta-agonists
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof
JP2025520449A (ja) * 2022-06-15 2025-07-03 バイキング セラピューティクス，インコーポレーテッド Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA2638753A1 (en) * 2004-12-08 2006-06-15 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
EP1987827A1 (en) * 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
HUE038366T2 (hu) * 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
EP3259246B1 (en) * 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
EP3423379B1 (en) * 2016-02-29 2020-04-01 Philip Morris Products S.a.s. Hinge-lid container and blank
CN109475121B (zh) * 2016-05-18 2021-06-25 俄勒冈健康科学大学 苏比替罗衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Steroid Biochemistry & Molecular Biology, 2009, Vol.116, pp.37-43.*

Also Published As

Publication number Publication date
AU2017252122A1 (en) 2018-11-15
EP3445372A4 (en) 2020-03-25
KR20190017748A (ko) 2019-02-20
AU2023202321A1 (en) 2023-05-11
CA3021677C (en) 2024-11-12
BR112018071559B1 (pt) 2024-02-06
CN113730421A (zh) 2021-12-03
WO2017185083A1 (en) 2017-10-26
CN110200978A (zh) 2019-09-06
US20190134069A1 (en) 2019-05-09
AU2023202321B2 (en) 2025-04-24
AU2017252122B2 (en) 2023-02-09
CA3021677A1 (en) 2017-10-26
CN109641003A (zh) 2019-04-16
EP3445372B1 (en) 2026-02-25
MX2018012904A (es) 2019-01-31
EP3445372A1 (en) 2019-02-27
JP2019515915A (ja) 2019-06-13
CN110200978B (zh) 2023-10-31
BR112018071559A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
US12440502B2 (en) Use of thyroid beta-agonists
AU2023202321B2 (en) Use of thyroid beta-agonists
KR20190125432A (ko) 글루타미나제 억제제를 사용하는 병용 요법
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
CA3067746A1 (en) Compositions and methods for modulating hair growth
JP7019585B2 (ja) 核酸プロドラッグ
HK40064933A (en) Use of thyroid beta-agonists
HK40013781A (en) Use of thyroid beta-agonists
HK40007271A (en) Use of thyroid beta-agonists
HK40013781B (zh) 甲状腺β-激动剂的应用
WO2017127417A1 (en) Phosphopantothenate compounds
HK1257604A1 (en) Conjoint therapies with inhibitors of glucose production

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200423

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211111

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220318

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220607

End annual number: 3

Start annual number: 1

PG1601 Publication of registration